Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 222
Filter
2.
Haemophilia ; 26 Suppl 3: 26-28, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32356342

ABSTRACT

Registries will enable cohort studies to be performed, which are usually considered to be the best quality of observational studies. The quality of data of registries can be increased if is it possible to merge results ('crosstalk') between registries. A prerequisite for that is an agreed uniform core set of data to be collected and uniform definitions on the items to be collected. This paper discusses problems and barriers with existing registries and provides recommendations from an EMA workshop (European Medicines Agency), for core common data sets and how to secure the quality of data collected. The PedNet registry including >2200 children with haemophilia is presented as an example of a registry/cohort study.


Subject(s)
Hemophilia A/epidemiology , Databases, Factual , Europe , Humans , Registries
3.
Paediatr Drugs ; 20(5): 455-464, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30128815

ABSTRACT

Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administrations are still necessary. The half-lives of these products have now been extended (EHL) by fusion with albumin, the Fc-portion of IgG, or by being PEGylated. This has been very successful for EHL-FIX, with 3-5 times longer half-life, and to a lesser degree for EHL-FVIII with a half-life extension of only 1.5 times the conventional products. New treatment principles using FVIII mimetics or monoclonal antibodies that rebalance the pro- and anti-coagulation system by interfering with production of anti-thrombin or tissue factor pathway inhibitor have the benefits of long-lasting activity, subcutaneous administration, and being useful in patients both with and without neutralizing antibodies. As the ultimate treatment, recent progress has also been made with gene therapy of both hemophilia A and B.


Subject(s)
Factor IX/therapeutic use , Factor VIII/therapeutic use , Hemophilia A/prevention & control , Hemophilia B/prevention & control , Child , Factor IX/pharmacokinetics , Factor VIII/pharmacokinetics , Genetic Therapy , Half-Life , Humans
4.
Ned Tijdschr Geneeskd ; 1622018 May 02.
Article in Dutch | MEDLINE | ID: mdl-30020568

ABSTRACT

Palliative sedation is increasingly being utilised when patients are close to death. Despite clear guidelines, its implementation is often problematic. In this clinical lesson we describe two patients in whom sedation did not go according to plan. The first case concerns a relative overdose of the medication which resulted in agitation, and the second case concerns the premature initiation of palliative sedation which caused the period of sedation to last too long. Suggestions are made to prevent these problems occurring.


Subject(s)
Conscious Sedation/adverse effects , Hypnotics and Sedatives/adverse effects , Medical Errors/prevention & control , Palliative Care/methods , Terminal Care/methods , Humans
5.
Br J Haematol ; 180(4): 501-510, 2018 02.
Article in English | MEDLINE | ID: mdl-29270992

ABSTRACT

Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A or B, who has developed an inhibitor. There are also some final outlooks on new and emerging treatment possibilities.


Subject(s)
Blood Coagulation Factor Inhibitors , Hemophilia A/diagnosis , Hemophilia A/therapy , Hemophilia B/diagnosis , Hemophilia B/therapy , Isoantibodies , Adult , Age Factors , Blood Coagulation Factor Inhibitors/blood , Blood Coagulation Factor Inhibitors/immunology , Child , Disease Management , Factor IX/genetics , Factor IX/immunology , Factor IX/therapeutic use , Factor VIII/genetics , Factor VIII/immunology , Factor VIII/therapeutic use , Hemophilia A/complications , Hemophilia A/genetics , Hemophilia B/complications , Hemophilia B/genetics , Hemorrhage/etiology , Hemorrhage/prevention & control , Hemorrhage/therapy , Humans , Isoantibodies/blood , Isoantibodies/immunology , Risk Assessment , Severity of Illness Index
6.
Interact Cardiovasc Thorac Surg ; 24(4): 549-554, 2017 04 01.
Article in English | MEDLINE | ID: mdl-28108578

ABSTRACT

Objectives: Both kaolin- and Celite-activated clotting times (ACT) are used to guide anticoagulation during cardiopulmonary bypass. It is unknown whether these methods lead to similar management procedures for anticoagulation in patients and are thus interchangeable in terms of bias, precision and variability. Methods: We randomized 97 patients undergoing coronary artery bypass grafting or aortic valve replacement to either kaolin- or Celite-guided anticoagulation. The ACT was measured simultaneously with the other method. We administered 300 IU/kg heparin to obtain initial ACT values greater than 400 s and additional heparin in each group using the minimum value of duplicate measurements according to a predefined protocol. The primary end point was the total heparin dose and the number of heparin supplements. Results: The total heparin dose per patient in the 48 Celite-guided patients was 35 271 ± 12 406 IU with 51 supplements and in the 49 kaolin-guided patients, 35 997 ± 11 540 IU ( P = 0.77) with 56 supplements ( P = 0.53). Postoperative thrombin generation time, fibrinolytic response time, chest tube loss and transfusion requirements were not different between the two groups. However, the methods differed in individual patients with regard to supplemental heparin ( P = 0.002). Bias between methods at baseline was +10.3%, Celite being higher, and changed to a value of -12.9% at 2 h bypass. The coefficient of variation at baseline for individual patients was 2.6 times larger with kaolin than with Celite ( P < 0.001). Correlation between ACT values at baseline was only 45%. Conclusions: Kaolin- and Celite-guided management of anticoagulation is clinically not different, but the methods are not interchangeable. Clinical registration number: www.trialregister.nl identifier 1738.


Subject(s)
Anticoagulants/therapeutic use , Cardiopulmonary Bypass , Coronary Artery Bypass , Diatomaceous Earth/therapeutic use , Heart Valve Prosthesis Implantation , Kaolin/therapeutic use , Aged , Blood Transfusion , Female , Heparin/therapeutic use , Humans , Male , Middle Aged , Prospective Studies , Whole Blood Coagulation Time
8.
Endocr Pract ; 21(4): 330-8, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25932566

ABSTRACT

OBJECTIVE: To study the long-term effectiveness of a patient-centered, multidisciplinary lifestyle intervention treatment in patients medically eligible for bariatric surgery. METHODS: Using a case-control study design, we compared treatment results for 98 adults (mean body mass index [BMI], 44.2 kg/m(2)) with the outcomes of 148 controls (mean BMI, 43.0 kg/m(2)) receiving standard care. The approach included a phased triage for inclusion, followed by 12 lifestyle intervention group sessions alternating with individual visits for behavior, diet, and exercise instructions. RESULTS: At 2 years, weight loss averaged 15.3 ± 1.4 kg (P<.0010) (12 ± 1% of initial body weight [IBW], P<.001; 21 ± 2% of excess body weight [EBW], P<.001) in an intention-to-treat (ITT) analysis; in completers, weight loss was 18.8 ± 1.5 kg (P<.001) (15 ± 1% IBW, P<.001; 26 ± 3% EBW, P<.001). A total of 42 patients lost ≥10% IBW. Controls remained weight stable (P = .35); 3% lost ≥10% IBW. Patients achieving weight loss that would be considered satisfactory for bariatric surgery included 20% who achieved ≥35% EBW loss, 29% who achieved a BMI <35 kg/m(2) (if starting BMI <50 kg/m(2)) or BMI <40 kg/m(2) (if starting BMI ≥50 kg/m(2)), and 37% who achieved EBW loss ≤50%. These values for completers were 31, 39, and 48%, respectively. In the 55 patients starting the program ≥4 years ago, weight loss maintenance of 12 ± 1% IBW (ITT, 16 ± 1% in completers) was observed. CONCLUSION: Substantial nonsurgical weight loss, maintained at 2 to 4 years, is achievable in severely obese patients using comprehensive lifestyle approaches; the efficacy/safety trade-off in obesity treatment is an important consideration in interpreting these results.


Subject(s)
Life Style , Obesity/therapy , Weight Loss , Body Mass Index , Case-Control Studies , Female , Humans , Male , Middle Aged
9.
Mar Environ Res ; 101: 161-168, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25440786

ABSTRACT

PAH metabolites present in bile are well-known biological markers of exposure in fish, and their investigation is recommended by the ICES (International Council for the Exploration of the Sea) and the OSPAR convention (Convention for the Protection of the Marine Environment of the North-East Atlantic) for monitoring purposes. Development of analytical strategies for fish bile is encouraged by the need for more sensitive and informative markers (e.g., capable of tracking the PAH composition of contamination sources) and strengthened by recent results in both fish genomics and proteomics. Herein, the study of the Atlantic cod bile proteome is presented. Preliminary testing for discovering new sensitive markers in the form of expressed proteins affected by PAH exposure (i.e., PAH-protein adducts) is reported. Protein markers were identified using LC-MS/MS analysis, as single biological indicators. Through multivariate analyses, the overall proteome was revealed to be a sensitive multi-biological marker of exposure to PAHs.


Subject(s)
Bile/metabolism , Fish Proteins/metabolism , Gadus morhua/metabolism , Polycyclic Aromatic Hydrocarbons/toxicity , Proteome/drug effects , Animals , Biomarkers/chemistry , Biomarkers/metabolism , Environmental Monitoring/methods , Fish Proteins/chemistry , Multivariate Analysis , Seawater/chemistry
10.
Environ Toxicol Chem ; 33(9): 1946-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24889815

ABSTRACT

Polar organic chemical integrative samplers (POCIS) were deployed in the vicinity of an offshore oil installation and analyzed for naphthenic acids (NAs). The POCIS accumulated a range of mono- to tetracyclic NAs, with different degrees of alkylation, with monocyclic acids being the most abundant. Currently, POCIS or similar polar samplers may be the only way to measure exposure to NAs from offshore discharges in situ. In addition, they may be a valuable tool for monitoring similar organic acids in general.


Subject(s)
Carboxylic Acids/analysis , Environmental Monitoring/instrumentation , Oil and Gas Fields/chemistry , Water Pollutants, Chemical/analysis , Water/analysis
11.
Europace ; 16(1): 101-8, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23833046

ABSTRACT

AIMS: Drug-induced long QT syndrome (diLQTS) leading to Torsade de Pointes (TdP) is a potentially lethal condition, which has led to several post-marketing drug withdrawals in the past decade. The true incidence of diLQTS/TdP is largely unknown. One explanation is under-reporting of this potentially life-threatening adverse event by physicians and other medical staff to pharmacovigilance agencies. To gain more insight into the incidence of diLQTS and TdP, the Berlin Pharmacovigilance Center (PVZ-FAKOS) has actively and prospectively identified patients who developed this particular type of drug-induced adverse event. Here, the basic characteristics of the affected patients are summarized and suspected drugs are discussed. Furthermore, an extrapolation of the Berlin incidence rates to the German Standard Population is presented. METHODS AND RESULTS: Using a Berlin-wide network of 51 collaborating hospitals (>180 clinical departments), adult patients presenting with long QT syndrome (LQTS/TdP) between 2008 and 2011 were identified by active surveillance of these hospitals. Drug exposures as well as other possible risk factors were obtained from the patient's files and in a face-to-face interview with the patient. One-hundred and seventy patients of possible LQTS/TdP were reported to the Pharmacovigilance Center of whom 58 cases were confirmed in a thorough validation process. The majority (66%) of these cases were female and 60% had developed LQTS/TdP in the outpatient setting. Thirty-five (60%) of 58 confirmed cases were assessed as drug-related based on a standardized causality assessment applying the criteria of the World Health Organization. Drugs assessed as related in more than two cases were metoclopramide, amiodarone, melperone, citalopram, and levomethadone. The age-standardized incidence of diLQTS/TdP in Berlin was estimated to be 2.5 per million per year for males and 4.0 per million per year for females. CONCLUSION: While European annual reporting rates based on spontaneous reports suggest an annual diLQTS/TdP incidence of 0.26 per million in Germany, we estimated a considerably higher incidence of diLQTS/TdP in an active surveillance approach. Further measures are warranted to better sensitize physicians against this potentially life-threatening drug-induced adverse event.


Subject(s)
Drug-Related Side Effects and Adverse Reactions/mortality , Long QT Syndrome/epidemiology , Torsades de Pointes/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Causality , Comorbidity , Female , Germany/epidemiology , Humans , Incidence , Male , Middle Aged , Risk Factors , Sex Distribution , Survival Analysis , Survival Rate , Young Adult
13.
Nutrients ; 4(8): 1137-50, 2012 08.
Article in English | MEDLINE | ID: mdl-23016136

ABSTRACT

The effect of progesterone (P4) on fructose rich diet (FRD) intake-induced metabolic, endocrine and parametrial adipose tissue (PMAT) dysfunctions was studied in the adult female rat. Sixty day-old rats were i.m. treated with oil alone (control, CT) or containing P4 (12 mg/kg). Rats ate Purina chow-diet ad libitum throughout the entire experiment and, between 100 and 120 days of age drank ad libitum tap water alone (normal diet; CT-ND and P4-ND) or containing fructose (10% w/v; CT-FRD and P4-FRD). At age 120 days, animals were subjected to a glucose tolerance test or decapitated. Plasma concentrations of various biomarkers and PMAT gene abundance were monitored. P4-ND (vs. CT-ND) rats showed elevated circulating levels of lipids. CT-FRD rats displayed high (vs. CT-ND) plasma concentrations of lipids, leptin, adiponectin and plasminogen activator inhibitor-1 (PAI-1). Lipidemia and adiponectinemia were high (vs. P4-ND) in P4-FRD rats. Although P4 failed to prevent FRD-induced hyperleptinemia, it was fully protective on FRD-enhanced plasma PAI-1 levels. PMAT leptin and adiponectin mRNAs were high in CT-FRD and P4-FRD rats. While FRD enhanced PMAT PAI-1 mRNA abundance in CT rats, this effect was absent in P4 rats. Our study supports that a preceding P4-enriched milieu prevented the enhanced prothrombotic risk induced by FRD-elicited high PAI-1 production.


Subject(s)
Diet/adverse effects , Fructose/pharmacology , Plasminogen Activator Inhibitor 1/metabolism , Progesterone/metabolism , Animals , Blood Glucose , Cholesterol/blood , Corticosterone/blood , Fatty Acids, Nonesterified/blood , Female , Fructose/chemistry , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Glucose Tolerance Test , Insulin/blood , Leptin/blood , Plasminogen Activator Inhibitor 1/genetics , Rats , Rats, Sprague-Dawley , Testosterone/blood , Triglycerides/blood
14.
Pharmacogenomics ; 13(12): 1351-61, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22966885

ABSTRACT

AIM: The adrenolytic agent mitotane is widely used in the treatment of adrenocortical cancer; however, its mechanism of action is poorly elucidated. We have studied mitotane-induced mRNA expression changes in the NCI-H295R adrenocortical cancer cell line. MATERIALS & METHODS: Cell viability and hormone assays were used to select the optimal mitotane concentration effectively inhibiting hormone secretion without affecting cell viability. RNA isolated from cultures treated for 48 and 72 h was subjected to Agilent 4×44K microarray platforms. Microarray results were validated by quantitative reverse-transcription PCR. RESULTS: Altogether, 117 significantly differentially expressed genes were detected at 48 h and 72 h (p < 0.05) in mitotane-treated samples relative to controls. Three significantly underexpressed genes involved in steroid hormone biosynthesis (HSD3B1, HSD3B2 and CYP21A2) and four significantly overexpressed genes (GDF15, ALDH1L2, TRIB3 and SERPINE2) have been validated. CONCLUSION: Gene-expression changes might be involved in the adrenal action of mitotane and in the inhibition of hormone secretion.


Subject(s)
Adrenal Cortex Neoplasms/genetics , Antineoplastic Agents, Hormonal/pharmacology , Gene Expression/drug effects , Hormones/genetics , Mitotane/pharmacology , Adrenal Cortex/drug effects , Adrenal Cortex Neoplasms/drug therapy , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/genetics , Gene Expression/genetics , Humans , Microarray Analysis/methods , RNA, Messenger/genetics
15.
PLoS One ; 7(3): e33686, 2012.
Article in English | MEDLINE | ID: mdl-22442710

ABSTRACT

BACKGROUND: In cardiac surgery, cardiopulmonary bypass (CPB) and unfractionated heparin have negative effects on blood platelet function. In acute normovolemic haemodilution autologous unfractionated heparinised blood is stored ex-vivo and retransfused at the end of the procedure to reduce (allogeneic) transfusion requirements. In this observational study we assessed whether platelet function is better preserved in ex vivo stored autologous blood compared to platelet function in the patient during CPB. METHODOLOGY/PRINCIPAL FINDING: We measured platelet aggregation responses pre-CPB, 5 min after the start of CPB, at the end of CPB, and after unfractionated heparin reversal, using multiple electrode aggregometry (Multiplate®) with adenosine diphosphate (ADP), thrombin receptor activating peptide (TRAP) and ristocetin activated test cells. We compared blood samples taken from the patient with samples taken from 100 ml ex-vivo stored blood, which we took to mimick blood storage during normovolemic haemodilution. Platelet function declined both in ex-vivo stored blood as well as in blood taken from the patient. At the end of CPB there were no differences in platelet aggregation responses between samples from the ex vivo stored blood and the patient. CONCLUSION/SIGNIFICANCE: Ex vivo preservation of autologous blood in unfractionated heparin does not seem to be profitable to preserve platelet function.


Subject(s)
Anticoagulants/pharmacology , Blood Platelets/metabolism , Blood Preservation , Blood Transfusion, Autologous , Cardiopulmonary Bypass , Heparin/pharmacology , Aged , Female , Humans , Male , Middle Aged , Platelet Function Tests
16.
Br J Haematol ; 157(5): 519-28, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22390160

ABSTRACT

Invasive procedures can be performed safely in children with haemophilia due to the availability of factor VIII/IX for patients without inhibitors. Most guidelines are based on the experiences in adults, but still there is no established consensus on the optimal factor levels or duration of replacement therapy for adults undergoing surgery. Few publications have focused on surgery in children with haemophilia. Children who have developed inhibitors to factor VIII/IX have to be treated with bypassing agents and constitute a group at higher risk for bleeding complications during surgery. The aim of this review is to summarize the experiences and opinions in the literature on replacement treatment of children with haemophilia, with and without inhibitors, during and after surgery, with a focus on the most prevalent clinical situations.


Subject(s)
Factor IX/therapeutic use , Factor VIII/therapeutic use , Hemophilia A/surgery , Hemophilia B/surgery , Hemostasis, Surgical , Antibodies/immunology , Child , Child, Preschool , Factor IX/immunology , Factor VIII/immunology , Hemophilia A/drug therapy , Hemophilia A/immunology , Hemophilia B/drug therapy , Hemophilia B/immunology , Humans
17.
Eur J Endocrinol ; 166(6): 1069-77, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22457236

ABSTRACT

OBJECTIVE: Hypopituitarism is associated with an increased mortality rate but the reasons underlying this have not been fully elucidated. The purpose of this study was to evaluate mortality and associated factors within a large GH-replaced population of hypopituitary patients. DESIGN: In KIMS (Pfizer International Metabolic Database) 13,983 GH-deficient patients with 69,056 patient-years of follow-up were available. METHODS: This study analysed standardised mortality ratios (SMRs) by Poisson regression. IGF1 SDS was used as an indicator of adequacy of GH replacement. Statistical significance was set to P<0.05. RESULTS: All-cause mortality was 13% higher compared with normal population rates (SMR, 1.13; 95% confidence interval, 1.04-1.24). Significant associations were female gender, younger age at follow-up, underlying diagnosis of Cushing's disease, craniopharyngioma and aggressive tumour and presence of diabetes insipidus. After controlling for confounding factors, there were statistically significant negative associations between IGF1 SDS after 1, 2 and 3 years of GH replacement and SMR. For cause-specific mortality there was a negative association between 1-year IGF1 SDS and SMR for deaths from cardiovascular diseases (P=0.017) and malignancies (P=0.044). CONCLUSIONS: GH-replaced patients with hypopituitarism demonstrated a modest increase in mortality rate; this appears lower than that previously published in GH-deficient patients. Factors associated with increased mortality included female gender, younger attained age, aetiology and lower IGF1 SDS during therapy. These data indicate that GH replacement in hypopituitary adults with GH deficiency may be considered a safe treatment.


Subject(s)
Hormone Replacement Therapy , Human Growth Hormone/adverse effects , Human Growth Hormone/deficiency , Hypopituitarism/mortality , Adult , Aged , Female , Hormone Replacement Therapy/adverse effects , Human Growth Hormone/administration & dosage , Humans , Hypopituitarism/drug therapy , Hypopituitarism/etiology , Insulin-Like Growth Factor I/metabolism , Male , Middle Aged , Poisson Distribution
18.
Thromb Res ; 130(2): 163-5, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22261478

ABSTRACT

INTRODUCTION: Bivalirudin is used as an alternative to heparin in cardiac surgery, and may be superior to heparin with regard to platelet function. Bivalirudin however, is prone to cleavage by thrombin resulting in coagulation in areas of stasis. MATERIAL AND METHODS: We compared the preservation of platelet function and the quality of anticoagulation in autologous blood of 26 cardiac surgical patients collected intraoperatively and anticoagulated ex vivo with either bivalirudin or heparin, with supplementation of bivalirudin over time and prevention of stasis. RESULTS: We found in both preservatives a reduction in ADP-induced platelet aggregation response over a period of 105 minutes (median, IQR: 73-141) as measured by Multiplate®. Supplementation of additional bivalirudin (23 ± 1.1 µg/ml/hr) and prevention of stasis was not able to prevent thrombin generation. We found a 5-fold increase in levels of prothrombin fragment 1+2 in bivalirudin preserved autologous blood as compared to heparin preserved blood (F(1+2) levels median 8.9 nM [quartile percentiles 4.2-12.4] vs 1.3 nM [0.6-2.1], P=0.001 Mann-Whitney, n=10). CONCLUSIONS: Our study suggests that preservation of platelet function in autologous blood anticoagulated with bivalirudin is not a suitable alternative to heparin.


Subject(s)
Anticoagulants/pharmacology , Blood Platelets/drug effects , Blood Preservation/methods , Heparin/pharmacology , Hirudins/pharmacology , Peptide Fragments/pharmacology , Aged , Blood Platelets/cytology , Humans , Middle Aged , Peptide Fragments/metabolism , Platelet Aggregation/drug effects , Prothrombin/metabolism , Recombinant Proteins/pharmacology
19.
Mar Pollut Bull ; 64(1): 144-152, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22070981

ABSTRACT

Biological markers of produced water (PW) exposure were studied in Atlantic cod (Gadus morhua) in both laboratory and field experiments, using authentic PW from a North Sea oil field. In the laboratory study, the PW exposure yielded significantly elevated levels of metabolites of polycyclic aromatic hydrocarbons (PAHs) and alkylphenols (APs) in bile even at the lowest exposure dose (0.125% PW). Other biomarkers (hepatic CYP1A induction and DNA adduct formation) responded at 0.25% and 0.5% PW concentrations. In the field study, bile metabolite markers and hepatic CYP1A were clearly increased in fish caged close to the PW outfall. Induction of plasma vitellogenin was not found in laboratory or field exposures, suggesting that the levels of oestrogen agonists (such as APs) might not have been sufficient to elicit induction, under the present conditions. The applicability of the biomarkers for use in water column biomonitoring programs is discussed.


Subject(s)
Gadus morhua/metabolism , Industrial Waste/adverse effects , Water Pollutants, Chemical/toxicity , Animals , Bile/metabolism , Biomarkers/metabolism , Cytochrome P-450 CYP1A1/metabolism , DNA Adducts/metabolism , Environmental Monitoring , Extraction and Processing Industry , Liver/metabolism , North Sea , Petroleum/analysis , Petroleum/metabolism , Petroleum/toxicity , Phenols/toxicity , Polycyclic Aromatic Hydrocarbons/analysis , Polycyclic Aromatic Hydrocarbons/metabolism , Polycyclic Aromatic Hydrocarbons/toxicity , Seawater/chemistry , Vitellogenins/metabolism , Water Pollutants, Chemical/analysis , Water Pollutants, Chemical/metabolism
20.
Mar Environ Res ; 75: 2-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22142721

ABSTRACT

Concern has been raised over whether environmental release of alkylphenols (AP) in produced water (PW) discharges from the offshore oil industry could impose a risk to the reproduction of fish stocks in the North Sea. An environmental risk assessment (ERA) was performed to determine if environmental exposure to PW APs in North Sea fish populations is likely to be high enough to give effects on reproduction endpoints. The DREAM (Dose related Risk and Effect Assessment Model) software was used in the study and the inputs to the ERA model included PW discharge data, fate information of PW plumes, fish distribution information, as well as uptake and elimination information of PW APs. Toxicodynamic data from effect studies with Atlantic cod (Gadus morhua) exposed to APs were used to establish a conservative environmental risk threshold value for AP concentration in seawater. By using the DREAM software to 1) identify the areas of highest potential risk and 2) integrate fish movement and uptake/elimination rates of APs for the chosen areas we found that the environmental exposure of fish to APs from PW is most likely too low to affect reproduction in wild populations of fish in the North Sea. The implications related to risk management of offshore PW and uncertainties in the risk assessment performed are discussed.


Subject(s)
Fishes/physiology , Phenols/toxicity , Reproduction/drug effects , Water Pollutants, Chemical/toxicity , Animals , Computer Simulation , Environmental Exposure/adverse effects , Environmental Exposure/analysis , Extraction and Processing Industry , Industrial Waste , Models, Theoretical , North Sea , Norway , Petroleum , Waste Disposal, Fluid
SELECTION OF CITATIONS
SEARCH DETAIL
...